Latest News
Cybin, MindMed are set to launch expanded human studies after recent trial setbacks for Lykos, Compass
As psychedelic treatments gain traction, analysts predict triple-digit upside for this small-cap biotech stock.
MindMed is a high-flying pre-revenue company that has more than doubled investor returns in the last 12 months.
Discover three under-the-radar biotech and medtech stocks that analysts believe could soar in 2024, each with unique growth drivers and significant upside potential.
This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher
For investors with a high level of risk tolerance, Mind Medicine could be an intriguing investment option.
Canadian-incorporated companies Cybin, MindMed among those seeking US regulatory OK to treat mental disorders after generating strong results in human trials
Mind Medicine is a pre-revenue biopharma company that has more than doubled investor returns in 2024. Is MNMD stock a good buy today?
Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder
/CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative...
This May be One of the Biggest Catalysts for Psychedelic Stocks in 2024
About 43.8 million adults in the U.S. experience a mental health issue in a given year, according to the National Institute of Mental Health (NAMI). Nearly 16 million of those adults live with major depression. Another 18.1% live with anxiety...
Breaking: The US FDA Just Granted Priority Review of an MDMA Treatment for PTSD
At the moment, about 14 million people live with PTSD just in the U.S. Unfortunately, despite extensive clinical research, PTSD is still a significant unmet medical need. However, that may soon change with the US FDA’s acceptance of a New...
Here's a closer look at three low-priced stocks - MNMD, ASPN, and BEEM - that Wall Street is expecting to double (or more) from current levels.
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise
/PRNewswire/ -- The demand for abuse deterrent formulation technology is projected to grow due to growing misuse of drugs among the people. Growing demand for...
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
/PRNewswire/ -- Psychedelic and hallucinogenic medicines market have been growing consistently over the past several years and are expected to continue to rise...
Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed's Phase 2B study evaluating MM-120
/PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and...
MindMed Reports First Quarter 2023 Financial Results and Business Highlights
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the...
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
The Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today...
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a...
MindMed to Participate in May Investor Conferences
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s...
MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has filed its...
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)
Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced today that Prof. Matthias Liechti and Dr. Felix...
MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Mark R....
MindMed Reports Full Year 2022 Financial Results and Business Highlights
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the...